A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.


Updates from The Motley Fool

Latest updates on Seattle Genetics from Fool.com.  The Fool has written over 100 articles on Seattle Genetics.


Stock Performance

View Interactive SGEN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Seattle Genetics.
Current Price: $71.80
Prev Close: $73.72
Open: $74.03
Bid: $71.50
Ask: $96.99
Day's Range: $70.71 - $74.15
52wk Range: $47.75 - $84.37
Volume: 668,923
Avg Vol 903,441
Market Cap: $10B
P/E (ttm): -254.21
EPS (ttm): -$0.29
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Seattle Genetics.
CAPS Rating 4 out of 5
 
468 Outperform
31 Underperform
CAPS All Stars
 
85 Outperform
7 Underperform

How do you think Seattle Genetics will perform against the market?



You pick for Seattle Genetics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Clay B. Siegall, CEO

90% Approve

Based on 45 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Seattle Genetics.

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers